Last update: Jan. 3, 2021
Minimal risk for breastfeeding and infant.
It is a non-cardioselective beta blocker
It is used in the treatment of glaucoma and ocular hypertension, hypertension, angina and myocardial infarction, in the prophylactic treatment of migraine and as a topical treatment for infantile hemangiomas.
Administration in eye drops or oral once or twice a day.
After oral or ophthalmic administration it is excreted in breast milk in clinically insignificant amounts (Madadi 2008, Lustgarten 1983, Fidler 1983) and no problems have been observed in infants whose mothers have taken it (Johnson 2001, Lustgarten 1983).
Absorption should be minimized by closing the eye after instillation, applying pressure for 1 to 5 minutes with your finger on the tear duct at the inner corner of the eye and administering the dose immediately after nursing (Blumen 2020, Belkin 2020, Johnson 2001).
The manufacturer considers ophthalmic use compatible with breastfeeding (Novartis 2020).
American Academy of Pediatrics: medication usually compatible with breastfeeding (AAP 2001).
List of WHO essential medicines: compatible with breastfeeding (WHO / UNICEF 2002).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM